In this Issue
- Psychedelic Safety Takes Centre Stage in Berkeley
- Selection Bias and Small Sample Size Hampers Compass Pathways’ Long-Term Psilocybin Data
- Placebo Outperforms LSD in MindMed’s Microdosing Study for ADHD
- atai Bets on Bitcoin
- Potential Tweak to Ukrainian Law Could Permit Psychedelic Research
- Governor of Virginia Vetoes Compass Pathways Rescheduling Bill
- Other Stories, including: Psilocybin may help phantom limb pain; psychedelic research benefits from Canadian Cancer Society Funding; British drag queen’s death sharpens focus on ketamine.
***
Psychedelic Safety Takes Centre Stage in Berkeley
Last week, I (Psychedelic Alpha Editor, Josh Hardman) attended the Psychedelic Safety Summit at my alma mater (well, year-abroad-mater), UC Berkeley. It was great to be back on campus, especially alongside a fantastic group of folks from across the psychedelics field.
Chatham House-type rules limit my reporting of specifics, with attributed remarks not permitted. The organisers were planning, I believe, to release a media-friendly report following each day of the summit, but that appears to have got lost in the shuffle that organising such a packed event entails.
The Summit, supported primarily by the Educational Foundation of America with additional contribution from the William G Nash Foundation, drew a diverse crowd of 150-odd. Those participants included psychedelic industry figures, researchers of various stripes, psychedelic harm reductionists, Indigenous people, government workers, and others.
Aside from the Summit participants, also in attendance were volunteers, ‘stewards’, and facilitators—all of which would have been worthy ‘participants’ themselves.
The organisers certainly did a good job of attracting such an impressive crowd, though some attendees wondered how that process had worked (the Summit did not accept applicants).
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
